Charlotte Teunissen, PhD, Amsterdam University Medical Centers, Amsterdam, Netherlands shares recent findings from the Netherlands Twin Registry that demonstrate the predictive value of plasma biomarkers for amyloid positivity in people as early as aged 58. Blood samples obtained 10 years prior to cerebrospinal fluid (CSF)/PET amyloid analysis showed there were differences in baseline amyloid beta, GFAP and phospho-tau levels between individuals who went on to test amyloid-positive and amyloid-negative at the 10-year follow-up. Longitudinal increases in phospho-tau and GFAP were also seen in those that went on to test amyloid-positive. Additionally, GFAP levels at the time of CSF/PET analysis were significantly related to decline in cognition in the 2-4 years that followed. This interview took place at the Alzheimer’s Association International Conference (AAIC) 2022 in San Diego, CA.